VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Promising agents in AML: menin inhibitors & magrolimab in TP53-mutated AML

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares his excitement for the development of menin inhibitors in acute myeloid leukemia (AML) and for upcoming data on the efficacy of magrolimab in TP53-mutated AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter